New Study Reveals Who Was More Vulnerable to Post-COVID Syndrome in Early Phases of the Pandemic

Fatigue, malaise and difficulty breathing were associated with post-COVID syndrome, according to the new Nordic study.

ImageJohnér bildbyrå

"These scientific results are an important step in better understanding PCS. By identifying key factors, we can improve diagnosis, adapt care and pave the way for research into more effective treatments," says Anne-Marie Fors Connolly, MD PhD, Assoc Prof, clinical researcher at Umeå University and the study's senior author.

The study analyzed data from over one million people in Sweden who tested positive for COVID-19 during the period from February 2020 to May 2021. Of these, 1.5 percent, just over 16,000 people, were diagnosed with PCS after the main COVID-19 infection. They were diagnosed in both outpatient and inpatient care, which provided large datasets for the researchers to examine the clinical footprint of PCS. The researchers conducted an in-depth study of PCS symptoms in individuals who required ongoing healthcare three months after the COVID-19 infection.

The researchers found that the most common symptoms associated with PCS were dyspnoea (difficulty breathing), malaise, and fatigue, as well as abnormal lung examination findings. People with PCS were more likely to have hypertension and high blood pressure compared to both people who had undergone COVID-19 infection without later being diagnosed with PCS and compared to people who had not contracted COVID-19 at all. This indicates a vulnerability in people with high blood pressure. Notably, dyspnoea emerged as a new symptom for the majority of those diagnosed with PCS, underscoring its significance in PCS symptomatology and how clinicians diagnose PCS.

In determining which COVID-19 patients were diagnosed with post-COVID syndrome, a strong correlation was observed with the severity of illness during the early stages of infection. In particular, individuals who required mechanical ventilation for breathing assistance were at high risk of being diagnosed with PCS after recovering from the COVID-19 infection.

The study's comprehensive approach, leveraging data from multiple nationwide registries, provides a unique overview of PCS and valuable insights for healthcare providers. The results underline the importance of future studies on the underlying causes and potential treatments of PCS.

"Our study elucidates symptomatology and how clinicians diagnose PCS. Understanding the clinical and demographic characteristics of PCS is crucial to develop targeted care strategies for those suffering from long-term effects of COVID-19," says Dr. Hanna Ollila, FIMM-EMBL Group Leader at the University of Helsinki.

The study is developed within the EU-funded research project NeuroCOV and is additionally funded by the Swedish Research Council and Academy of Finland. Led by Umeå University, it involves institutions in four Nordic countries, including the Swedish and Finnish nodes of the Nordic EMBL Partnership for Molecular Medicine, the Laboratory for Molecular Infection Medicine Sweden (MIMS) and the Institute for Molecular Medicine Finland (FIMM) at University of Helsinki.